University of Helsinki at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
University of Helsinki brings 4 presentations to ESGCT 2026 in Hamburg. Its work centres on oncolytic adenoviruses for cancer immunotherapy and on what treating patients with them has shown. Other strands cover rewiring macrophages to improve responses in colorectal cancer and lipid nanoparticles or base editing aimed at pancreatic beta cells.
| Organization | ESGCT 2026 Attendance |
|---|---|
University of Helsinki Helsinki, Finland | |
Finnish university whose groups develop oncolytic adenoviruses for cancer immunotherapy. | Talk Wed Oct 28 8:30am–10:30am Oncolytic adenoviruses in humans, what have we learned from treatment of > 500 patients with viruses such as Oncos-102 and TILT-123? Cancer gene and cell therapyClinical trials and translation Chair Wed Oct 28 8:30am–10:30am SESSION 3c: Oncolytic therapy & cancer gene therapy Cancer gene and cell therapy Talk Wed Oct 28 10:00am–10:30am Poster Wed Oct 28 1:30pm–3:30pm Ligand-conjugated lipid nanoparticles for specific delivery to pancreatic beta cells Poster Thu Oct 29 2:00pm–4:00pm Adenine base editing of Ins1 to prevent autoimmune beta cell destruction in NOD mice |
Instantly find 20 buyers from University of Helsinki
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction